Singapore markets closed
  • Straits Times Index

    3,208.86
    -8.55 (-0.27%)
     
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • Dow

    33,507.50
    -158.80 (-0.47%)
     
  • Nasdaq

    13,219.32
    +18.02 (+0.14%)
     
  • Bitcoin USD

    28,301.31
    +1,119.87 (+4.12%)
     
  • CMC Crypto 200

    607.11
    +28.34 (+4.90%)
     
  • FTSE 100

    7,567.64
    -40.44 (-0.53%)
     
  • Gold

    1,853.70
    -12.40 (-0.66%)
     
  • Crude Oil

    91.39
    +0.60 (+0.66%)
     
  • 10-Yr Bond

    4.6350
    +0.0620 (+1.36%)
     
  • Nikkei

    31,759.88
    -97.72 (-0.31%)
     
  • Hang Seng

    17,809.66
    +436.66 (+2.51%)
     
  • FTSE Bursa Malaysia

    1,418.76
    -5.41 (-0.38%)
     
  • Jakarta Composite Index

    6,961.46
    +21.57 (+0.31%)
     
  • PSE Index

    6,304.53
    -16.71 (-0.26%)
     

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

Here's How Moderna Plans to Win in the Post-Emergency COVID Vaccine Market

High demand for coronavirus vaccines earlier in the pandemic pushed Moderna's (NASDAQ: MRNA) earnings into the stratosphere. In fact, Moderna could continue to generate billions in revenues annually from its first -- and so far, only -- approved product. For example, Moderna sold its vaccine to the U.S. government for about $26 a dose.